Clinical Characteristics and Differential Clinical Diagnosis of Novel Coronavirus Disease 2019 (COVID-19)

Novel Coronavirus Disease (COVID-19) has become a rapidly growing pandemic involving several nations. It is of serious concern and extreme challenge not only to the health personnel but also to the countries for containment. The causative organism is SARS-CoV-2, RNA virus of subgenus Sarbecovirus, similar to the SARS virus, and seventh member of the human coronavirus family responsible for this zoonotic infection. It binds to the human angiotensin converting enzyme (hACE-2) receptor and causes constitutional and respiratory symptoms. The major mode of transmission is human to human and the median incubation period is 4 days. The most common symptom as studied from various cohorts of COVID-19 patients are fever (83–98%) followed by fatigue (70%) and dry cough (59%); gastrointestinal symptoms are relatively uncommon differentiating it from SARS and MERS. Most of the SAR-CoV-2 infection are mild (80%) with a usual recovery period of 2 weeks. COVID-19 commonly affects males in the middle age and elderly age group, with highest case fatality (8–15%) among those aged >80 years. The disease begins with fever, dry cough, fatigue and myalgia progressing to dyspnoea and ARDS over 6 and 8 days post exposure, respectively. Underlying co-morbidities increase mortality in COVID-19. Poor prognostic factors are elderly, co-morbidities, severe lymphopaenia, high CRP and D-dimer >1 μg/L. The overall mortality rate ranges from 1.5 to 3.6%. COVID-19 has to be differentiated from other viral and bacterial pneumonias as they are more common among healthy adults. Despite constant and vigorous efforts by researchers and health agencies, we are far from containment, cure or prevention by vaccine; hence right information and stringent prevention and control measures are the only weapon in the armoury to combat the ongoing infection.

[1]  P. Klepac,et al.  Early dynamics of transmission and control of COVID-19: a mathematical modelling study , 2020, The Lancet Infectious Diseases.

[2]  Ting Yu,et al.  Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study , 2020, The Lancet.

[3]  K. Yuen,et al.  Clinical Characteristics of Coronavirus Disease 2019 in China , 2020, The New England journal of medicine.

[4]  Ryuji Uozumi,et al.  Viral Pneumonia Requiring Differentiation from Acute and Progressive Diffuse Interstitial Lung Diseases , 2019, Internal medicine.

[5]  J. Xiang,et al.  Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study , 2020, The Lancet.

[6]  C. del Rio,et al.  COVID-19-New Insights on a Rapidly Changing Epidemic. , 2020, JAMA.

[7]  Zunyou Wu,et al.  Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. , 2020, JAMA.

[8]  Bulk and single-cell transcriptomics identify tobacco-use disparity in lung gene expression of ACE2, the receptor of 2019-nCov , 2020, medRxiv.

[9]  G. Gao,et al.  A Novel Coronavirus Genome Identified in a Cluster of Pneumonia Cases — Wuhan, China 2019−2020 , 2020, China CDC weekly.

[10]  Macfarlane Burnet,et al.  Natural history of infectious disease , 1953 .

[11]  Huixia Yang,et al.  Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: a retrospective review of medical records , 2020, The Lancet.

[12]  Heshui Shi,et al.  Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study , 2020, The Lancet Infectious Diseases.

[13]  Fei Deng,et al.  Discovery of a novel coronavirus associated with the recent pneumonia outbreak in humans and its potential bat origin , 2020, bioRxiv.

[14]  E. Giamarellos‐Bourboulis,et al.  Macrophage Activation-Like Syndrome: A Distinct Entity Leading to Early Death in Sepsis , 2019, Front. Immunol..

[15]  G. Wong,et al.  SARS-CoV-2 Infection in Children , 2020, The New England journal of medicine.